Chester County News and Community Website
WILMINGTON, DE — Ashland Inc. (NYSE: ASH) announced it will release its fourth-quarter fiscal 2025 financial results at approximately 5 p.m. ET on Tuesday, November 4, 2025. The company will …
Ashland to Report Fourth-Quarter Fiscal 2025 Results on November 4 Read More
PORTO, Portugal & WILMINGTON, DE — Naoris Protocol has announced the launch of Naoris Ventures, a new venture arm designed to accelerate the adoption of decentralized, post-quantum security infrastructure across …
Naoris Protocol Launches Venture Arm to Advance Post-Quantum Security Adoption Read More
WILMINGTON, DE — InterDigital, Inc. (Nasdaq: IDCC) announced two key licensing agreements that extend the reach of its intellectual property portfolio — a renewed patent license with Sharp and a …
InterDigital Expands Licensing Portfolio With Sharp Renewal and New EV Charging Deal Read More
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo reported that their antibody-drug conjugate ENHERTU® (fam-trastuzumab deruxtecan-nxki), when used before surgery and followed by standard therapy, achieved a pathologic complete response in …
ENHERTU Combination Shows Promising Results in Early Breast Cancer Trial Read More WILMINGTON, DE — Levitask has announced the development of its patent-pending T-Mech mechanism, an ergonomic innovation designed to bridge the gap between sitting and standing. The system introduces a new …
Levitask Unveils Patent-Pending T-Mech Mechanism, Introducing New Era of Elevated Seating Read More WILMINGTON, DE — AstraZeneca and Amgen have received U.S. Food and Drug Administration (FDA) approval for TEZSPIRE® (tezepelumab-ekko) as an add-on maintenance treatment for adults and adolescents aged 12 and …
AstraZeneca and Amgen Secure FDA Approval for TEZSPIRE to Treat Chronic Rhinosinusitis with Nasal Polyps Read More
WILMINGTON, DE — The Bancorp, Inc. (NASDAQ: TBBK) announced that it will release its third quarter 2025 financial results after the market closes on Thursday, October 30. The company will …
The Bancorp to Report Third Quarter 2025 Financial Results on October 30 Read More WILMINGTON, DE — AstraZeneca announced that its IMFINZI (durvalumab) regimen significantly reduced the risk of disease recurrence or death by 32 percent in patients with high-risk, non-muscle-invasive bladder cancer (NMIBC) …
IMFINZI Combination Cuts Disease Recurrence Risk by 32% in Early Bladder Cancer Trial Read More WILMINGTON, DE — AstraZeneca announced new data from its Phase III MATTERHORN trial showing that its immunotherapy IMFINZI (durvalumab), when used in combination with standard FLOT chemotherapy, reduced the risk …
AstraZeneca Reports IMFINZI-Based Regimen Cuts Death Risk by 22% in Early Gastric Cancer Read More
WILMINGTON, DE — The Chemours Company (NYSE: CC) announced that it will release its third-quarter 2025 financial results after the market closes on Thursday, November 6, 2025.
Chemours to Release Third-Quarter 2025 Financial Results on November 6 Read More